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Cocaine is a highly addictive drug that acts upon the
brain’s reward circuitry via the inhibition of mono-
amine uptake. Endogenous cannabinoids (eCB)
are lipid molecules released from midbrain dopa-
mine (DA) neurons that modulate cocaine’s effects
through poorly understood mechanisms. We find
that cocaine stimulates release of the eCB, 2-arach-
idonoylglycerol (2-AG), in the rat ventral midbrain
to suppress GABAergic inhibition of DA neurons,
through activation of presynaptic cannabinoid CB1
receptors. Cocaine mobilizes 2-AG via inhibition of
norepinephrine uptake and promotion of a coopera-
tive interaction between Gq/11-coupled type-1 me-
tabotropic glutamate and a1-adrenergic receptors
to stimulate internal calcium stores and activate
phospholipase C. The disinhibition of DA neurons
by cocaine-mobilized 2-AG is also functionally rele-
vant because it augments DA release in the nucleus
accumbens in vivo. Our results identify a mechanism
through which the eCB system can regulate the
rewarding and addictive properties of cocaine.
INTRODUCTION
The ventral tegmental area (VTA) is a central component of a
mammalian brain reward circuit involved in processing environ-
mental information to ensure survival. The VTA contains neurons
that project extensively to the forebrain and release dopa-
mine (DA). These neurons mediate the rewarding properties
of all abused drugs (Di Chiara and Imperato, 1988; Wise and
Rompre, 1989) and shift their activity from pacemaker to burst
firing during exposure to drugs or stimuli predicting drug avail-
ability (Cooper, 2002; Covey et al., 2014). This enhancement of
DA neuron activity results in increased DA in projection sites,
such as the nucleus accumbens (NAc), which is critical to drug
reinforcement (Di Chiara and Bassareo, 2007; Phillips et al.,
2003).
Cannabinoid CB1 receptors (CB1R) are coupled to G-pro-
teins, are extensively expressed on axon terminals in the CNS,
and inhibit release of excitatory and inhibitory neurotransmittersCell Repto sculpt postsynaptic activity (Alger and Kim, 2011; Kano et al.,
2009). CB1Rs are also activated by the primary psychoactive
constituent of cannabis, D9-tetrahydrocannabinol (D9-THC), to
mediate the physiological and psychotropic effects of this
drug in humans (Hoffman and Lupica, 2013). Molecules, known
as endogenous cannabinoids (eCBs), derived from membrane
phospholipids, also activate CB1Rs to mediate short- and
long-term forms of synaptic plasticity (Kano et al., 2009). Anan-
damide (Devane et al., 1992) and 2-arachidonoylglycerol
(2-AG) (Mechoulam et al., 1995) are the best characterized
eCBs, with 2-AG most closely associated with activity-depen-
dent modulation of synapses (Kano et al., 2009). 2-AG can be
mobilized during transient postsynaptic increases in Ca2+
through activation of voltage-dependent Ca2+ channels (Kreitzer
and Regehr, 2001; Maejima et al., 2001; Ohno-Shosaku et al.,
2001; Wilson and Nicoll, 2001). This type of 2-AG release medi-
ates depolarization-induced suppression of inhibition (DSI) or
excitation (DSE), in which 2-AG from postsynaptic cells acts
to retrogradely activate CB1Rs on axon terminals to inhibit
GABA or glutamate release, respectively. 2-AG synthesis can
also be triggered through activation of Gaq/11-coupled metabo-
tropic receptors via their coupling to phospholipase C-b (PLCb).
PLCb hydrolyzes phosphatidylinositol 4,5-bisphosphate to form
1,2-dacylglycerol (DAG) and inositol triphosphate. DAG is then
hydrolyzed by diacylglycerol lipase-a (DGLa) to form 2-AG (Ha-
shimotodani et al., 2005; Kano et al., 2009; Maejima et al.,
2005). Receptor-mediated 2-AG release can also be strongly
augmented by coincident elevation of intracellular Ca2+ (Hashi-
motodani et al., 2007; Kano et al., 2009; Maejima et al., 2005).
eCBs are released from VTA DA neurons during depolariza-
tion (Melis et al., 2004) or conditions promoting burst activity
(Riegel and Lupica, 2004). Furthermore, DGLa is strategically
located on postsynaptic membranes adjacent to presynaptic
CB1Rs in the VTA (Ma´tya´s et al., 2008). All abused drugs,
including D9-THC, increase DA release in forebrain areas such
as the NAc. The cannabinoid-induced increase in DA likely
occurs through an increase in VTA DA neuron firing rate and
bursting (French et al., 1997; Gessa et al., 1998). Since cannabi-
noids act at CB1Rs in the VTA to inhibit the release of the inhib-
itory neurotransmitter GABA (Riegel and Lupica, 2004; Szabo
et al., 2002), we hypothesize that disinhibition of VTA DA neu-
rons leads to increases in their activity and phasic release of
DA in the NAc (Cheer et al., 2007; Lupica et al., 2004; Riegel
and Lupica, 2004).orts 12, 1997–2008, September 29, 2015 ª2015 The Authors 1997
Figure 1. Tonic Inhibition of GABA Signaling
in VTA DA Neurons Is Mediated by 2-AG
(A) Sample traces (left) and time-courses of GABAB
IPSCs (right) during CB1R ligand treatment;
CB1R agonist WIN55,212-2 (WIN, 1 mM), CB1R
antagonist/inverse agonist, AM251 (2 mM), and
neutral antagonist PIMSR1 (2 mM). Gray traces in
all figures indicate those during treatment. Gray
area in time course indicates period of drug
application. Scale bar, 100 ms, 10 pA.
(B) Summary of CB1R ligand effects on GABAB
IPSCs (F(2,14) = 30.75, p < 0.0001, one-way
ANOVA, *p < 0.01, **p < 0.001, Tukey’s post hoc).
(C) The AM251-mediated increase in GABAB
IPSCs is prevented by inclusion of the DGL inhib-
itor, THL (5 mM), in the pipette (*p < 0.05, unpaired t
test). Scale bar, 100 ms, 10 pA.
(D) The AM251-induced increase of GABAB IPSCs
is enhanced by the MAG lipase inhibitor JZL184
(10 mM; **p < 0.01, unpaired t test). Scale bar,
100 ms, 10 pA.The eCB system also regulates the rewarding actions of many
abused drugs (Lupica and Riegel, 2005). Antagonism of CB1Rs
reduces drug-induced reward-related behavior and the associ-
ated elevation of NAc DA (Cheer et al., 2007; Li et al., 2009).
The rewarding property of the psychostimulant cocaine is pri-
marily attributed to its ability to increase forebrain DA levels via
inhibition of the DA transporter (DAT) (Ritz et al., 1987; Thomsen
et al., 2009). However, because cocaine-induced elevations of
DA release events depend on VTA DA neuron firing (Sombers
et al., 2009) and eCB signaling (Cheer et al., 2007), eCB release
in the VTA may be critical to cocaine reinforcement.
Here, we find that cocaine mobilizes 2-AG, which then acti-
vates CB1Rs to inhibit GABA release onto DA neurons, and
that cocaine’s ability to elevate NAc DA in awake rats is attenu-
ated by disruption of 2-AG signaling. Mobilization of 2-AG by
cocaine depends on activation of Gq/11-coupled receptors, initi-
ation of Ca2+ oscillations, and activation of PLC.We propose that
cocaine increases DA in the NAc and reinforces behavior, in part,
through disinhibition of DA neurons via suppression of GABA
release by cocaine-induced 2-AG mobilization.
RESULTS
Inhibition of GABA Release onto VTA DA Neurons
by 2-AG
IPSCs mediated by GABAB receptors on VTA DA neurons (S1a)
are inhibited by presynaptic CB1Rs (Riegel and Lupica, 2004).
Here, the synthetic CB1R agonist WIN55,212-2 (1 mM) inhibited
GABAB IPSCs (77.9% ± 3.9% of control, n = 5; p < 0.05, paired
t test) (Figures 1A and 1B). These responses were also increased
by theCB1Rantagonist/inverse agonist, AM251 (2 mM;115.4%±
1.6% of control, n = 6; p < 0.01, paired t test), suggesting that
eCBs tonically inhibitGABAB IPSCs.BecausemanyCB1Rantag-
onists, such as AM251, are also inverse agonists (Landsman1998 Cell Reports 12, 1997–2008, September 29, 2015 ª2015 The Authorset al., 1997), their reversal of eCB effects
may instead reflect allosteric modulation
of CB1Rs. However, a ‘‘neutral’’ CB1Rantagonist, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
3-[(E)-piperidinoiminomethyl]-1H-pyrazole (PIMSR1; 2 mM)
(Hurst et al., 2006) also increased GABAB IPSCs in putative DA
neurons (121.3% ± 5.7% of control, n = 6; p < 0.05, paired
t test). Moreover, this did not differ significantly from that pro-
duced by AM251 (p = 0.35, unpaired t test, Figures 1A and 1B).
This suggests that AM251 and PIMSR1 increased GABAB IPSC
amplitude through antagonism of tonically released eCB acting
at CB1Rs and not through allosteric modulation. As the effect
of AM251 did not differ from PIMSR1, it was used in subsequent
experiments.
We next determined which eCB exerted control over GABAB
IPSCs in putative VTA DA neurons. 2-AG is derived from
membrane phospholipids via the sequential activity of PLC and
DGLa (Kano et al., 2009). 2-AG is then inactivated by the enzyme
monoacylglycerol lipase (MGL) in presynaptic terminals. Inclu-
sion of the DGLa inhibitor tetrahdydrolipstatin (THL, 5 mM)
in the intra-pipette solution prevented the enhancement of
GABAB IPSCs by AM251 (AM251 = 140.7% ± 12.3%, n = 5;
AM251 + intra-THL = 104.9% ± 7.7%, n = 6; unpaired t test,
p < 0.05; Figure 1C). In contrast, the increase in GABAB IPSCs
produced by AM251 was significantly larger in the presence of
the MGL inhibitor JZL184 (10 mM; AM251 alone = 115.4% ±
1.6% of control, n = 6; AM251 + JZL184 = 132.6% ± 3.9% of
control, n = 5; unpaired t test, p < 0.01; Figure 1D). This demon-
strates that 2-AG is tonically released from putative DA neurons
to inhibit GABAB IPSCs via activation of CB1Rs.
Cocaine Increases DA Transients in the NAc via eCB
Action in the VTA
Systemic cocaine administration increases DA transient signals
measured by fast scan cyclic voltammetry (FSCV) in the NAc
and this is attenuated by systemic administration of the CB1R
antagonist, rimonabant (SR141716A) (Cheer et al., 2007). Since
Figure 2. Cocaine-Induced Increase in NAc DA Transients Require
CB1R Activation in VTA
(A) Voltammetric current (encoded in color) plotted against the applied carbon-
fiber electrode potential (ordinate) and the acquisition time (abscissa). Traces
above color plots represent current (normalized to concentration) from the
potential where DA is oxidized (+0.6 V in green), when animals are given an
i.v. bolus of cocaine (1 mg/kg), preceded by intra-VTA vehicle infusion.
(B) Systemic effects of cocaine are attenuated following CB1R blockade in
VTA (250 ng rimonabant [Rbt] in 500 ml, unilateral and ipsilateral to the
recording electrode).
(C) Effects of all treatments on NAc DA transient frequency (F(4,31) = 29.14, p <
0.0001, one-way ANOVA; n = 12 rats). Baseline indicates the frequency of DA
transients without intracranial or systemic injections. In other groups the intra-
VTA injection is indicated first, followed by the i.v. injection (e.g., intracranial
Vehyintra-VTA Veh). Note that Rbt alone (Rbt/Veh) did not alter DA transient
frequency, and Rbt significantly reduced the effect of i.v. cocaine on DA
transients (Rbt/cocaine, ***p < 0.0001, Bonferroni post hoc test).DA neurons do not express CB1Rs (Ma´tya´s et al., 2008), the ef-
fects of cocaine are likely presynaptic to these cells. Moreover,
as CB1Rs are expressed on GABA axon terminals in the VTA
(Ma´tya´s et al., 2008; Riegel and Lupica, 2004; Szabo et al.,
2002), we hypothesize that cocaine releases eCBs in the VTA
to inhibit GABA release onto DA neurons to disinhibit these cells.
To determine whether the eCB-dependent effects of cocaine
occur through actions in the VTA, NAc DA transients were
measured during intravenous (i.v.) cocaine administration in vivo
and the effect of intra-VTA rimonabant tested (Figure 2). A
one-way ANOVA for all combinations of intra-VTA and i.v. injec-
tions revealed a significant treatment effect (F(4,31) = 29.14, p <
0.0001). Under baseline conditions, NAc DA transients occurred
at 0.028 ± 0.007 Hz, and as reported previously, were signifi-
cantly increased by i.v. cocaine during intra-VTA vehicle infusion
(cocaine + vehicle = 0.176 ± 0.01 Hz; p < 0.0001, Bonferroni postCell Rephoc comparison; Cheer et al., 2007). Injection of rimonabant into
the VTA prior to i.v. cocaine significantly reduced this increase
in DA transients (cocaine + rimonabant = 0.082 ± 0.10 Hz, n =
6 rats; p < 0.0001, Bonferroni post hoc comparison; Figure 2C).
Moreover, intra-VTA rimonabant alone did not alter the fre-
quency of NAc DA transients (0.032 ± 0.003 Hz, p > 0.05, Bonfer-
roni post hoc comparison, Figure 2C).
2-AG-Mediated Inhibition of GABAB IPSCs by Cocaine
We next determined whether cocaine enhanced eCB release in
VTA in vitro and whether this reduced GABAergic input to DA
neurons. Cocaine (10 mM) significantly inhibited GABAB IPSCs
(67.5% ± 3.0% of control; n = 19; p < 0.0001, paired t test; Fig-
ures 3A and 3C) and this was significantly reduced by AM251
(2 mM; 87.2% ± 4.8% of control, n = 7; p < 0.01, one-way
ANOVA, Bonferroni post hoc analysis; Figures 3A and 3C).
Furthermore, the effects of cocaine on GABAB IPSCs reversed
when its application was stopped (Figures S1B and S1C). To
determine whether 2-AG was the eCB whose actions were
increased by cocaine, we examined the effects of the DGLa
inhibitor, THL on the inhibition of GABAB IPSCs produced by
cocaine. Cocaine’s inhibition of GABAB IPSCs was not signifi-
cantly reduced by THL (5 mM) when included in the intra-pipette
solution (intra-THL: 75.0% ± 2.7% of control; p > 0.05, one-way
ANOVA, Bonferroni post hoc analysis, n = 9; Figures 3B and 3C).
However, extracellular application of THL (10 mM) significantly
reduced the inhibitory effect of cocaine on GABAB IPSCs (ex-
tra-THL = 85.6% ± 4.7% of control, n = 5; p = 0.009, paired t
test; p < 0.05, one-way ANOVA, Bonferroni post hoc analysis;
Figures 3B and 3C). This suggests that cocaine releases 2-AG
from sites that are more widely distributed than those involved
in tonic inhibition of GABAB IPSCs under control conditions
(Figure 1C).
The main site eCBs act in the CNS is at CB1Rs on axon termi-
nals to suppress neurotransmitter release (Kreitzer and Regehr,
2001; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). To
determine whether eCB-dependent effects of cocaine on
GABAB IPSCs were presynaptic we measured GABA-mediated
postsynaptic currents elicited by laser (355 nm) photolysis of
O-(CNB-Caged) GABA (100–200 mM). Light-evoked GABAB cur-
rents were not altered by cocaine (control: 23.79 ± 4.85 pA;
cocaine: 22.38 ± 4.74 pA; n = 7; p > 0.05, paired t test; Figure 3D),
suggesting that inhibition of electrically evoked GABAB IPSCs by
cocaine occurred presynaptically.
We next determined whether 2-AG in the VTA mediates the
increase in NAc DA transients during cocaine application in vivo
using THL injection in VTA. A one-way ANOVA for all combi-
nations of intra-VTA and i.v. injections revealed a significant
treatment effect (F(4,10) = 9.395, p = 0.002). Under baseline con-
ditions, DA transients occurred at 0.044 ± 0.003 Hz and this was
significantly increased by i.v. injection of cocaine and intra-VTA
vehicle infusion (cocaine + vehicle = 0.094 ± 0.007 Hz; p <
0.001, Bonferroni post hoc comparison, Figure 3G). Intra-VTA
THL significantly reduced the increase in DA transients by
cocaine (cocaine + THL = 0.05 ± 0.011 Hz, n = 3 rats; p <
0.001, Bonferroni post hoc comparison; Figure 3G). Moreover,
intra-VTA THL alone did not alter the frequency of DA transients,
compared to pre-cocaine baseline (0.045 ± 0.006 Hz, p > 0.05,orts 12, 1997–2008, September 29, 2015 ª2015 The Authors 1999
Figure 3. Cocaine-Mobilized 2-AG Inhibits GABA Release and Increases DA Release in NAc via Actions in VTA
(A) Acute cocaine (10 mM) perfusion inhibited GABAB IPSCs and this was partially blocked by AM251 (2 mM). Scale bar, 100 ms, 10 pA.
(B) Cocaine inhibition of GABAB IPSCs was reduced by inhibition of DGL with THL, applied either intracellularly via the pipette (intra-THL) or extracellularly, by
addition to the aCSF (extra-THL). Scale bar, 100 ms, 10 pA.
(C) Summary of the experiments shows significant reduction of the cocaine inhibition of GABAB IPSCs by AM251 and THL (n = 5; F(3,36) = 6.35, p = 0.0014,
one-way ANOVA; *p < 0.05 and **p < 0.01, Bonferroni post hoc analysis).
(D) Cocaine did not affect postsynaptic GABAB currents evoked by laser (indicated by vertical bar on sweeps inset) uncaging of O-CNB-Caged-GABA
(100–200 mM in bath; n = 7, p > 0.05, paired t test. Scale bar, 100 ms, 10 pA.
(E) In vivo NAc FSCV current (encoded in color) is plotted against the applied potential (ordinate) and the acquisition time (abscissa). Traces above color plots are
extracted currents (normalized to concentration) from the potential where DA is oxidized (+0.6 V shown in green), when animals are given intravenous cocaine
(1 mg/kg), preceded by an i.c.v. vehicle injection.
(F) Effects of cocaine are reduced in vivo by inhibition of 2-AG synthesis by THL in the VTA (750 ng THL in 500 ml, unilateral and ipsilateral to the recording
electrode).
(G) Intra-VTA THL reduces DA transient frequency elicited by i.v. cocaine (F (4,10) = 9.395, p = 0.002, one-way ANOVA; n = 3 rats, **p < 0.001, Bonferroni post hoc
analysis). Baseline indicates DA transient frequency without intracranial or systemic injections. In other groups, the intra-VTA injection is indicated first, followed
by the i.v. injection condition (e.g., intracranial Vehyintra-VTA Veh). Note that THL alone (THL/Veh) did not alter DA transient frequency, and THL significantly
reduced the effect of i.v. cocaine on DA transients (THL/cocaine, p < 0.001, Bonferroni post hoc test).
See also Figure S1.Bonferroni post hoc comparison, Figure 3G). Consistent with
the in vitro experiments, these data suggest that cocaine en-
hances 2-AG levels in the VTA to disinhibit DA neurons, contrib-
uting to increased DA release in the NAc.
Cocaine-Induced 2-AG Signaling Is Independent of 5-HT
and DA
Our study shows that AM251 and THL do not completely prevent
inhibition of GABA release produced by cocaine (Figure 3), and
another study shows that cocaine inhibits GABA release onto
DA neurons in VTA by inhibiting serotonin (5-HT) reuptake and
activation of 5-HT1B/D receptors (Cameron and Williams, 1994).
Therefore, we determined whether the effects of cocaine on
2-AG involved 5-HT. The 5-HT1 receptor agonist sumatriptan
(300 nM) decreased GABAB IPSCs (71.42% ± 4.50% of control,
n = 8) and largely occluded the inhibition produced by cocaine
(cocaine alone = 67.53% ± 3.01% of control, n = 19; sumatrip-
tan + cocaine = 91.51% ± 3.52% of control, n = 8; p < 0.001,2000 Cell Reports 12, 1997–2008, September 29, 2015 ª2015 The Aone-way ANOVA, Bonferroni post hoc analysis; Figures 4A, 4D,
and 4G). The 5-HT1B/D antagonist, GR55562 (1 or 10 mM) had
no effect alone on GABAB IPSCs but decreased the inhibition
of this response by cocaine (cocaine alone = 67.53% ± 3.01%
of control, n = 19; GR55562 + cocaine = 83.94% ± 3.91% of
control, n = 10; p < 0.05, one-way ANOVA, Bonferroni post
hoc analysis; Figures 4B and 4G). Additionally, the 5-HT uptake
inhibitor citalopram (10 mM) and the 5-HT releaser fenfluramine
(10 mM) both depressed GABAB IPSCs (citalopram: 77.77% ±
5.6% of control, n = 7; fenfluramine: 67.06% ± 3.42% of control,
n = 11; Figure 4D).
To determine whether the inhibition of GABAB IPSCs by the
5-HT system involves eCBs, we tested the effects of citalopram
and fenfluramine during AM251 application (Figure 4D). We
found that inhibition of GABAB IPSCs produced by these drugs
was unaffected by CB1R antagonism (citalopram + AM251 =
75.03% ± 6.10% of control, n = 6; fenfluramine + AM251 =
70.26% ± 3.74% of control, n = 8; p > 0.05, unpaired t test;uthors
Figure 4. Inhibition of GABAB IPSCs by Cocaine Is Independently Mediated by 5HT1B and CB1 Receptors
(A) Inhibition of GABAB IPSC by cocaine was largely occluded by the 5HT1B receptor agonist sumatriptan (300 nM).
(B) The selective 5HT1B receptor antagonist GR55562 (1 or 10 mM) suppressed the inhibition by cocaine.
(C) The inhibition by cocaine was completely abolished when CB1 and 5HT1B receptors were blocked simultaneously.
(D) Serotonin-induced depression of GABAB IPSC is independent of CB1Rs. Application of the 5HT1B agonist sumatriptan, the selective serotonin reuptake
inhibitor citalopram (10 mM), or the serotonin releaser fenfluramine (10 mM) all depressed GABAB IPSCs to a similar level. However, this is unaffected by the CB1R
antagonist AM251 (4 mM; F(2,46) = 0.25, p = 0.77, two-way ANOVA). Scale bar, 100 ms, 10 pA.
(E) Pre-treatment with the selective DA transport inhibitor, GBR12935 (1 mM), does not occlude the inhibition of GABAB IPSCs by cocaine.
(F) The DA-D2 receptor antagonist sulpiride (5 mM) does not prevent the inhibition by cocaine.
(G) Summary the effect of cocaine on GABAB IPSCswith different drug treatments (F(5,51) = 12.83, p < 0.0001, one-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 versus cocaine; #p < 0.05 versus GR55562; Bonferroni post hoc analysis). The complete elimination of the cocaine-induced inhibition of GABAB
IPSCs by CB1R and 5-HT1B antagonism indicates that these effects are independent.Figure 4D). Similarly, the effect of the 5-HT1 agonist sumatriptan
was not altered by AM251 (sumatriptan + AM251 = 74.07% ±
3.41% of control, n = 12; Figure 4D). Therefore, we conclude
that whereas cocaine enhances extracellular 5-HT levels to
activate 5-HT1 receptors and inhibit GABA release onto DA
neurons, this is independent of the inhibition produced by
cocaine via 2-AG. Therefore, the inhibition of GABA release by
cocaine in the VTA occurs via 2 independent mechanisms.
Consistent with this, co-application of the 5-HT1B/D antagonist
GR55562 and AM251 completely blocked the inhibition of
GABAB IPSCs produced by cocaine (AM251 + GR55562 +
cocaine = 101.09% ± 1.88% of control, n = 8; p < 0.0001 versusCell Repcocaine, one-way ANOVA; Figures 4C and 4G). Therefore, all
subsequent experiments examining cocaine mobilization of
2-AG, were performed during blockade of 5-HT1B/1D receptors
with GR55562 (1 mM).
Previous studies show that DA-D2 receptors stimulate 2-AG
release (Melis et al., 2004; Pan et al., 2008). Therefore, we exam-
ined the involvement of D2 receptors and DA in 2-AG-mediated
cocaine effects. In contrast to cocaine, the selectiveDAT inhibitor
GBR12935 (1 mM) increased GABAB IPSCs and surprisingly did
not occlude their inhibition by cocaine (GBR12935 + cocaine =
69.93% ± 4.67% of control, n = 7; Figures 4E and 4G). Similarly,
a DA-D2 antagonist, sulpiride (5 mM), did not change the inhibitionorts 12, 1997–2008, September 29, 2015 ª2015 The Authors 2001
Figure 5. Mobilization of 2-AG by Cocaine Requires Synergistic
Activation of mGluR1 and a1 Adrenergic Receptors and Activation of
Phospholipase C
All experiments were performed in the presence of GR55562 to block 5-HT1B
receptors.
(A) Inhibition of GABAB IPSCs by cocaine was blocked by AM251 (2 mM), the
mGluR1 antagonist JNJ16259685 (JNJ, 500 nM) and the a1R antagonist HEAT
(1 mM) (F(3,29) = 5.173, p = 0.0055, one-way ANOVA; *p < 0.05, Bonferroni post
hoc analysis).
(B) Co-application of the mGluR1 agonist DHPG (1 mM) and the a1 agonist
phenylephrine (PE, 100 mM) inhibited GABAB IPSCs, whereas alone these
agonists did not exhibit such effects. Pre-incubation of slices with AM251
significantly blocked the synergistic effect of DHPG and PE (F(3,26) = 20.19, p <
0.0001, one-way ANOVA; *p < 0.05, **p < 0.01, ****p < 0.0001, Bonferroni post
hoc analysis). Scale bar, 100 ms, 10 pA. Scale bar applies to (A).
(C) The NET inhibitor nisoxetine (10 mM) occluded the inhibition of GABAB
IPSCs by cocaine (*p < 0.05, unpaired t test). Scale bar, 100 ms, 10 pA.
(D) An inhibitor of PLC, U73122 (5 mM), significantly blocked the effect of
cocaine (*p < 0.05 versus cocaine, unpaired t test). Scale bar, 100 ms, 10 pA.
See also Figures S2 and S3.of GABAB IPSCs produced by cocaine (73.09% ± 5.45% of con-
trol, n = 5; Figures 4F and 4G). Therefore, the cocaine-induced
inhibition of GABAB IPSCs did not result from increased extracel-
lular DA levels or activation of DA-D2 receptors.
Gq/11-Coupled Receptor Involvement in the Cocaine-
Induced Release of 2-AG
Several studies show that Gaq/11-coupled receptors promote the
production of 2-AG in thebrain (Kanoet al., 2009; Kimet al., 2002;
Kortleven et al., 2011;Maejima et al., 2001). Therefore, we exam-
ined their involvement in cocaine-induced 2-AG mobilization.
Antagonists for Gq/11-coupled mGluR5, DA-D1, and neurotensin
receptors did not alter the cocaine-induced inhibition of GABAB
IPSCs in VTA DA neurons (Figure S2). However, antagonism of
Gq/11-coupled a1-adrenergic receptors (a1R) with 2-[[b-(-4-hy-2002 Cell Reports 12, 1997–2008, September 29, 2015 ª2015 The Adroxyphenyl)ethyl]aminomethyl]-1-tetralone) (HEAT, 1 mM) or
the selective, non-competitive, mGluR1 receptor antagonist,
(3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)-(cis-4-methoxycy-
clohexyl)-methanone (JNJ16259685 [JNJ]; 500 nM) completely
blocked the 2-AG-dependent inhibition of GABAB IPSCs pro-
moted by cocaine (cocaine = 83.94% ± 3.91% of control, n =
10; cocaine + HEAT = 99.68% ± 4.73% of control, n = 7;
cocaine + JNJ = 99.39% ± 4.49% of control, n = 8; p < 0.01,
one-way ANOVA, Bonferroni post hoc analysis; Figure 5A).
This indicates that activation of both mGluR1 and a1Rs during
cocaine application is required for the 2-AG-dependent inhibi-
tion of GABA release. We next examined the involvement of
these receptors using selective agonists.
The mGluR1 agonist, DHPG (1 mM), alone, significantly
increased the amplitude of GABAB IPSCs (123.80% ± 7.58%
of control, n = 5; p < 0.05, paired t test; Figure 5B), whereas
the a1R agonist, phenylephrine (PE, 100 mM) did not affect
these currents (96.52% ± 5.60% of control, n = 8; p = 0.52,
paired t test; Figure 5B). In contrast, co-application of DHPG
and PE strongly inhibited GABAB IPSCs (69.53% ± 3.66% of
control, n = 8; p < 0.001, paired t test; Figure 6B) and this
was significantly reduced by AM251 pretreatment (87.09% ±
2.36% of control, n = 9; p < 0.05 versus HEAT + PE, unpaired
t test; Figure 5B). This suggests that co-activation of Gq/11-
coupled mGluR1 and a1Rs is necessary for cocaine to promote
2-AG mobilization and inhibit GABA release onto VTA DA
neurons.
As cocaine is a potent inhibitor of the norepinephrine trans-
porter (NET), we next examined whether the a1R-dependent
effect of cocaine on GABAB IPSCs occurred via this mecha-
nism. The selective NET inhibitor, nisoxetine (10 mM), completely
blocked the inhibition of IPSCs produced by cocaine (99.31% ±
3.00% of control, n = 7; p < 0.05 versus cocaine, unpaired t test,
Figure 5C), suggesting that cocaine promotes activation of a1Rs
and the mobilization of 2-AG through the inhibition of NET.
Contribution of PLC-b and Intracellular Ca2+ to the
Cocaine Mobilization of 2-AG
The lipolytic enzyme, PLC-b, promotes conversion of phosphoi-
nositides to DAG,which can then be converted to 2-AG via DGLa
(Alger and Kim, 2011; Hashimotodani et al., 2005; Kano et al.,
2009). As PLCb is activated by a rise in internal Ca2+, or activa-
tion of Gq/11-coupled receptors, we determined whether PLC-b
inhibition alters the 2-AG inhibition of GABA release by cocaine.
The cocaine inhibition of GABAB IPSCs was absent in DA neu-
rons incubated in the PLC inhibitor, U73122 (5 mM; cocaine +
U73122 = 97.46% ± 3.20% of control, n = 7; p < 0.05, unpaired
t test, Figure 5D), suggesting that cocaine-induced 2-AG mobili-
zation requires PLC.
To assess the role of Ca2+ in the release of 2-AG by cocaine,
in vitro calcium imaging experiments were performed in VTA
DA neurons expressing the genetically-encoded calcium indica-
tor, GCaMP6f, in TH-Cre rats. Robust expression of GCaMP6f
was confirmed (Figure 6A), and DA neurons exhibiting stable
Ca2+-associated fluorescence and spontaneous Ca2+ oscilla-
tions were observed (Figures 6A and 6B; Movie S1). The mean
frequency of spontaneous calcium oscillations in a sub-group
of neurons (29.1%, 168 of 578 neurons) (Figure 6B; Movie S1)uthors
under resting conditions was 0.042 ± 0.002 Hz (range 0.0026–
0.167 Hz, Figures 6H and 6I). With bath application of cocaine
(10 mM), the Ca2+ signal in 21.2% (32 of 151) of the DA neurons
was unchanged, whereas it was reduced by cocaine in 59.6%
(90 of 151) of DA neurons (Figures 6C, 6D, and 6J; Movie S1).
Among this latter population, 47.8% (43 of 90) exhibited slow
calcium oscillations during baseline whose frequency was
reduced by cocaine (control = 0.041 ± 0.004 Hz; cocaine =
0.012 ± 0.003 Hz; p < 0.0001, paired t test; Figures 6C–6E).
The remaining neurons (19.2%, 29 of 151) exhibited no Ca2+ os-
cillations during baseline but demonstrated oscillations during
cocaine application (0.023 ± 0.004 Hz; p < 0.01 versus sponta-
neous oscillation, Kolmogorov-Smirnov [K-S] test; Figures
6C–6E and 6J). These cocaine-induced slow Ca2+ oscillations
(SO) exhibited lower frequencies and broader half-widths than
oscillations observed during baseline (spontaneous baseline
oscillation half-width = 11.21 ± 2.48 s; cocaine-induced oscilla-
tion half-width = 24.17 ± 3.19 s; p < 0.0001, K-S test; Figure 6F),
suggesting that cocaine SOs reflect distinct Ca2+ sources and/or
release mechanisms. The cocaine SOs were also more highly
synchronized among VTA DA neurons than the spontaneous
Ca2+ oscillations under baseline conditions, as indicated by
cross correlation analysis (Figure 6G).
In electrophysiological experiments, the cocaine-induced
depression of GABA release was mediated by 2-AG and
abolished by antagonism of mGluR1 or a1Rs (Figure 5A). There-
fore, we examined effects of these antagonists on cocaine-
induced changes in intracellular Ca2+. The mGluR1 antagonist,
JNJ16259685 (500 nM), prevented the cocaine-induced in-
crease in the Ca2+ SO, as only 4.1% (4 of 97 cells) of DA neurons
showed this response (Figure 6J, **p < 0.0001, chi-square test).
Moreover, the proportion of DA neurons showing no change in
intracellular Ca2+ with cocaine increased to 32.0% (31 of 97 neu-
rons, Figure 6J), and the proportion of VTADA neurons exhibiting
a decrease in Ca2+ signal upon cocaine application was not
altered by JNJ162959685 (63.9%, 62 of 97 neurons, Figure 6J).
The a1R antagonist, HEAT (1 mM), also prevented the increased
the cocaine-induced Ca2+ SO, as only 5.8% (5 of 86 neurons)
showed this response (Figure 6J, p < 0.0001, chi-square test).
However, unlike the mGluR1 antagonist, HEAT also reduced
the proportion of neurons exhibiting a decrease in Ca2+ oscilla-
tions (3.5%, 3 of 86, Figure 6J). The PLCb inhibitor, U73122,
also prevented the cocaine-induced SO, as only 5.0% (4 of 80
cells, Figure 6J, p < 0.0001, chi-square test) of the DA neurons
showed this effect.
The number of neurons showing an increase in Ca2+ SO with
cocaine was also reduced when intracellular stores were
depleted with the sarco/endoplasmic reticulum Ca2+ ATPase in-
hibitor, thapsigargin (2 mM; oscillation increase in 2.6%, 2 of 77
neurons, Figure 6J, p < 0.0001, chi-square test). Additionally,
the proportion of neurons showing inhibition of the Ca2+ signal
by cocaine was increased following thapsigargin (81.8%, 63 of
77 neurons; Figure 6J). The frequency of baseline Ca2+ oscilla-
tions was significantly reduced by JNJ162959685 (p = 0.0037
versus cocaine, K-S Test, Figures 6H and 6I), but unchanged
by HEAT, U73122, or thapsigargin (Figures 6H and 6I). However,
the percentage of neurons showing these oscillations in the
absence of cocaine was lower in U73122-treated slices andCell Rephigher in thapsigargin-incubated slices (control: 29.1%; HEAT:
22.0%; JNJ: 20.8%; U73122: 11.3%; thapsigargin: 43.6%;
Figure 6H).
Depletion of Internal Ca2+ Stores Blocks the
2-AG-Dependent Effects of Cocaine
To determine whether elimination of the cocaine-induced Ca2+
SOs also blocks the cocaine-mediated release of 2-AG, we
measured GABAB IPSCs after treatment with thapsigargin
(2 mM; Figure 6K). We found that thapsigargin prevented the
cocaine inhibition of GABAB IPSCs in DA neurons (95.63% ±
1.67% of control, n = 7; p < 0.05 versus cocaine alone, unpaired
t test; Figure 6K), confirming that internal Ca2+ is necessary for
cocaine-induced 2-AG mobilization.
DISCUSSION
Here, we find that cocaine mobilizes 2-AG in the VTA to inhibit
GABAergic inputs to GABAB receptors on DA neurons via pre-
synaptic CB1R activation. We also show that cocaine’s ability
to increase the frequency of DA transients in the NAc is depen-
dent on 2-AG synthesis and CB1R signaling in the VTA, collec-
tively implicating an eCB-dependent disinhibition of VTA DA
neurons. Our results thereby provide a mechanism to explain
the disruption of cocaine-motivated behavior that is observed
during antagonism of the eCB system in animal models of addic-
tion and relapse to drug seeking (De Vries et al., 2001; Li et al.,
2009; Soria et al., 2005; Xi et al., 2006, 2008). Based on these
findings, we hypothesize that cocaine-induced 2-AG mobiliza-
tion in the VTA facilitates DA release in the NAc to support
cocaine reinforcement.
The cocaine-induced inhibition of GABA release is disrupted
by several manipulations that target the eCB system in the
VTA, including (1) blockade of CB1Rs, (2) inhibition of PLCb,
and (3) inhibition of DGLa. We also find that 2-AG mobilization
by cocaine requires activation of both mGluR1 and a1Rs, since
antagonism of either receptor prevents inhibition of GABAB
IPSCs in DA neurons. As the inhibition of GABA release by
cocaine was blocked by a NET inhibitor, our data further sug-
gest that cocaine increases extracellular NE and activates
a1Rs through this mechanism. Prior studies show that cocaine
increases NE via inhibition of NET (Reith et al., 1997), and NE
neurons project to the VTA to form connections with DA neurons
(Jones et al., 1977; Mejı´as-Aponte et al., 2009). Moreover, ge-
netic elimination of a1Rs is associated with lower baseline levels
of DA and prevents psychostimulant-mediated increases in NAc
DA (Auclair et al., 2002). A more recent study shows that cocaine
increases extracellular NE in VTA to activate a1Rs, contributing
to excitation of DA neurons and DA release in the NAc (Goertz
et al., 2014). This, together with our data, suggests that modula-
tion of NE function in the VTA likely plays a critical role in the
behavioral effects of cocaine.
We also find that mGluR1s are critical for the 2-AG-dependent
effects of cocaine in the VTA. However, electrically-evoked
EPSCs in VTA DA neurons are unaffected by cocaine under
our recording conditions (Figure S3), suggesting that synaptic
glutamate release is not involved. Despite this, prior work shows
that cocaine increases glutamate concentrations measured viaorts 12, 1997–2008, September 29, 2015 ª2015 The Authors 2003
Figure 6. Cocaine-Induced Calcium Changes in VTA DA Neurons
(A) Superimposed fluorescent and transmitted light images showing the expression of GCaMP6f in VTA DA neurons 2–3 weeks after injection of the AAV-
GCaMP6f construct. Scale bar, 500 mm.
(B) Spontaneous slow calcium oscillations in VTA DA neurons. Left: confocal image of the GCaMP6f signal (2003). Scale bar, 50 mm. Right: example calcium
oscillations (DF/F0) in the same cell indicated in the dashed square at left. Scale bar, 30 s, 20%.
(C) Sample traces of calcium signals (DF/F0) in response to cocaine application (10 mM, indicated in gray). Three types of changes were observed: no change, a
decrease in spontaneous oscillations, and the initiation of slow oscillations (SO).
(D) Raster plot of oscillation events in 19 neurons imaged as in (B). Each vertical bar denotes the peak of an oscillation event. Each row exhibits the time course of
oscillation change in single neurons.
(E) Cumulative frequencies of spontaneous, cocaine-decreased, and cocaine-initiated slow oscillations (cocaine SO) in calcium signal. The curve shifts left to
slower frequencies in neurons whose calcium oscillations were decreased by cocaine (osc decrease versus spontaneous, p = 0.17, K-S test). The frequency of
cocaine-initiated SO was significantly lower than that of spontaneous oscillations (cocaine-initiated versus spontaneous, p < 0.01, K-S test). Spontaneous
oscillation, n = 43 neurons; oscillation decrease, n = 19 neurons; cocaine SO, n = 29 neurons recorded in eight brain slices from six rats.
(F) Cumulative distribution of half-widths of spontaneous, cocaine-decreased, and cocaine-initiated SO. Cocaine-initiated SO exhibit longer half-widths than
spontaneous oscillations. (cocaine SO versus spontaneous, p < 0.0001, K-S test). Spontaneous oscillation, n = 43 neurons; oscillation decrease, n = 19 neurons;
cocaine SO, n = 29 neurons recorded in eight brain slices from six rats.
(G) Increased correlation of calcium responses among neurons (same 19 neurons as D) during cocaine perfusion. Cross correlations among all neuron pairs were
calculated, and the peak correlation coefficient (r = 0 to 1) is color-coded to form the heat map. The data indicate that VTADA neuron calcium oscillations aremore
highly synchronized by cocaine.
(H) Cocaine-induced calcium oscillations depend on mGluR1, a1-adrenergic receptors, and internal calcium stores. The frequency of spontaneous calcium
oscillations is reduced by JNJ16259685 (500 nM), but is not altered by HEAT (1 mM), U73122, or thapsigargin (thaps, 2 mM), respectively (F(4,265) = 3.806, p = 0.005,
one-way ANOVA; control versus JNJ: p < 0.05, Bonferroni post hoc analysis). Each point represents the frequency of spontaneous Ca2+ oscillation from one
neuron; the box and vertical lines indicate quartiles, minimal, and maximal frequencies. The percentage of neurons exhibiting spontaneous oscillations is shown
for each treatment group.
(I) Cumulative distributions of the frequencies of spontaneous oscillations are only affected by JNJ (p = 0.0037, Kolmogorov–Smirnov test).
(J) Summary of the percentage of DA neurons responding to cocaine under control, JNJ16259685, HEAT, U73122, and thapsigargin treatments.
Numbers denote the percentage of neurons demonstrating indicated changes upon cocaine treatment. All treatments decreased the cocaine-induced Ca2+
oscillation.
(legend continued on next page)
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Figure 7. Putative Mechanism of Cocaine Mobilization of 2-AG and
Inhibition of GABA Neurotransmission in the VTA
Glutamate spillover under baseline conditions activates mGluR1s, and
a1-adrenergic receptors located on VTA DA neurons are activated by NE
whose clearance is prevented by cocaine blockade of the NET. This co-acti-
vation of Gq11-coupled mGluR1 and a1Rs cooperatively stimulates PLC-b
leading to DAG formation. DAG is then converted to 2-AG, via DGL-a, then
crosses the extracellular space through an unknown mechanism to activate
CB1Rs located on GABA axon terminals. Activation of these presynaptic
CB1Rs inhibits GABA release onto postsynaptic GABAB receptors, leading to
2-AG-mediated disinhibition of DA neurons. This increases DA transients in the
NAc to enhance the rewarding properties of cocaine.microdialysis (Kalivas and Duffy, 1995), and mGluR1s are
activated by glutamate in DA neurons using electrical stimula-
tion similar to ours (Fiorillo and Williams, 1998). Therefore, we
suggest that sufficient extracellular glutamate is present under
baseline conditions to activate mGluR1s and this cooperatively
interacts with a1Rs to stimulate 2-AG production.
Imaging of Ca2+ dynamics in TH-Cre rats with GCaMP6f
reveals that cocaine initiates Ca2+ SOs in 20% of VTA DA
neurons, whereas baseline spontaneous Ca2+ oscillations are
suppressed in most cells. Antagonism of either mGluR1s or
a1Rs with JNJ16259685 or HEAT, respectively, largely elimi-
nates the cocaine SOs; an effect also seen with blockade of
PLCb by U73122 or depletion of intracellular Ca2+ by thapsigar-
gin. Corresponding blockade of both cocaine-induced SOs and
inhibition of GABAB IPSCs by each of these manipulations
supports the idea that the 2-AG-dependent actions of cocaine
are related to an increase in Ca2+ activity and dependent on
cooperative mGluR1 and a1AR signaling.
The activity of PLCb is enhanced in neurons by intracellular
Ca2+ and this is synergistically increased by co-activation of
Gq/11-coupled receptors to greatly augment 2-AG mobilization
(Alger and Kim, 2011; Kano et al., 2009). Here, we show that
cocaine causes activation of Gq/11-coupled a1Rs in DA neurons
through an increase in extracellular NE via inhibition of NET. The
requirement for co-activation of mGluR1 and a1Rs suggests that
there is an interaction at the Gq/11-coupled receptor level that
increases the activity of PLCb to synergistically augment 2-AG
release. This cooperativity between mGluR1 and a1Rs in the in-
hibition of GABA release onto VTA DA neurons may serve as a(K) Pre-treatment of slices with thapsigargin (2 mM) significantly attenuates the inhi
shows averaged electrically evoked GABAB IPSC traces (n = 5) under control cond
black; those obtained during cocaine application are shown in gray. Scale bar, 1
See also Movie S1.
Cell Repcoincidence detector, such that when sufficient NE is present,
together with glutamate activation of mGluR1s, 2-AG is mobi-
lized to reduce GABAergic input, thereby enhancing DA neuron
activity via disinhibition. Consequently, this will amplify forebrain
DA release, as shown here, and potentially enhance the reinforc-
ing properties of cocaine.
Our data also suggest that the cocaine-induced 2-AG mobili-
zation occurs in the 20% of VTA DA neurons demonstrating
cocaine-inducedCa2+ oscillations. This, together with our obser-
vation that extracellular application of THL is more effective
at blocking the cocaine-induced inhibition of GABA release
than intracellular application, supports the idea that 2-AG is
released from this subset of neurons to more widely affect syn-
aptic inputs. Moreover, since GCaMP6f was expressed only in
DA neurons in our study, the possibility that cocaine releases
2-AG from non-DA neurons was not evaluated and therefore
remains a possibility.
The rewarding and abuse-related properties of cocaine are
thought to primarily result from inhibition of DA uptake in fore-
brain areas such as the NAc (Phillips et al., 2003; Ritz et al.,
1987; Sulzer, 2011; Thomsen et al., 2009). However, cocaine
also acts in the VTA to increase DA neuron firing rates and DA
release events in the NAc (Sombers et al., 2009), and these
events are decreased by systemic CB1R antagonists (Cheer
et al., 2007). DA transients result from burst firing that occurs
upon presentation of natural reward, cues that predict their avail-
ability or during administration of abused drugs (Aragona et al.,
2008; Cheer et al., 2007; Oleson et al., 2012; Phillips et al.,
2003; Roitman et al., 2004; Sombers et al., 2009) and function
to reinforce behavior (Steinberg et al., 2014). Here, we demon-
strate that the eCB influence on DA transients is likely mediated
by 2-AG acting at CB1Rs in the VTA, since intra-VTA administra-
tion of a CB1R antagonist, or an inhibitor of DGLa blocked this
effect of cocaine. Although inhibition of VTA DA neurons is the
most frequent response to cocaine in anesthetized rodents, an
increase in the bursting activity of a proportion of these cells is
consistently reported (Einhorn et al., 1988; Mejias-Aponte
et al., 2015). Furthermore, a much larger proportion of VTA DA
neurons is excited by cocaine in awake-freely moving rats,
compared to anaesthetized animals (Koulchitsky et al., 2012).
Our lab has shown that that conditions promoting burst firing
of DA neurons causes activity- and extracellular-Ca2+-depen-
dent eCB release that presynaptically inhibits GABA release
onto these cells (Riegel and Lupica, 2004). In accord with the
present observations that cocaine mobilizes 2-AG via Gq11-
dependent mechanisms to enhance the inhibition of GABA in-
puts to these cells, we suggest that the eCB system in the VTA
is an important component of a positive feedback mechanism
that is engaged during exposure to cocaine and contributes to
its rewarding properties. In this scheme (Figure 7), we propose
that blockade of NET by cocaine promotes activation of Gq/11-
coupled a1Rs and this, together with mGluR1 activation, initiates
2-AG release, which then suppresses GABA release to disinhibitbition of GABAB IPSCs by cocaine (n = 7; *p < 0.05, unpaired t test). Inset at right
itions (top) and after treatment with thapsigargin. Control sweeps are shown in
00 ms, 10 pA.
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VTA DA neurons. This disinhibition then promotes burst firing
of DA neurons, mobilizing additional 2-AG through an activity-
dependent mechanism. This then supports further activation
of these cells, via disinhibition, to augment DA neuron activity
and DA release in downstream projections. In this way, the
eCB system promotes strong activation of DA neurons to
contribute to the rewarding actions of cocaine. Therefore, the
mechanisms that we have identified in the present study may
be critical in the development of pharmacotherapies for psy-
chostimulant addiction that target the eCB system.
EXPERIMENTAL PROCEDURES
Animal protocols were conducted under NIH guidelines and were approved by
the NIDA Intramural Research Program Animal Care and Use Committee.
Slice Preparation
Male Sprague-Dawley rats, 15 to 21 days old (Charles Rivers) were decapi-
tated, their brains rapidly removed and transferred to an aerated (95% O2/
5% CO2), ice-cold solution (in mM: sucrose 220, KCl 2.5, MgCl2 7, CaCl2
0.5, NaH2PO4 1.25, NaHCO3 26, glucose 20). Horizontal slices containing
VTA (250 mM) were cut using a tissue slicer (VT1000, Leica), then transferred
to a holding chamber filled with oxygenated artificial CSF (aCSF; in mM:
NaCl 126, KCl 3, MgCl2 1.5, CaCl2 2.4, NaH2PO4 1.2, NaHCO3 26, glucose
11) at room temperature.
Confocal experiments used 2- to-3-month-old female TH-Cre rats. Two to
three weeks after bilateral injection of a GCaMP6f construct into the VTA,
rats were anesthetized by isoflurane and decapitated. Horizontal VTA slices
(230 mM) were cut in a solution containing (in mM) NMDG 93, KCl 2.5,
MgSO4 10, CaCl2 0.5, NaH2PO4 1.2, NaHCO3 30, glucose 25, HEPES 20,
sodium ascorbate 5, sodium pyruvate 3, thiourea 2; PH 7.2–7.4. Slices were
first incubated in this solution at 34C for 10–15 min and then transferred to
room temperature aCSF until imaging.
Electrophysiology
A slicewas transferred to a recording chamber and immersed in heated (32C),
flowing (2 ml/min), oxygenated aCSF. Slices were visualized with an upright
microscope equipped with differential interference contrast (DIC) optics
(BX51WI, Olympus). Recorded neurons were in lateral VTA, medial to the ter-
minal nucleus of the accessory optic tract and anterior to the third cranial
nerve. Whole-cell voltage-clamp recordings were made with an Axopatch
200B (Molecular Devices) amplifier. Pipettes (3–5 MU) were filled with (in
mM): K-gluconate 140, NaCl 2, MgCl2 1.5, HEPES 10, EGTA 0.1, Mg-ATP 4,
Na2-GTP 0.3, Tris-phosphocreatine 10 (pH 7.2), 290 mOSM. Cell-attached re-
cordings were performed with the same electrodes immediately after patch
formation to identify DA neurons by electrophysiological properties; sponta-
neous, pacemaker firing (1–4 Hz), and action potential widths >1.5 ms (Chieng
et al., 2011). DNQX (10 mM), D-AP5 (25 mM), picrotoxin (100 mM), and strych-
nine (1 mM) were present to block AMPA, NMDA, GABAA, and glycine recep-
tors, respectively. After rupture of the membrane patch, 5 stimuli at 40 Hz
(200–600 mA, 200 ms) were applied every 60 s, via a bipolar electrode placed
in anterior VTA, to evoke GABAB receptor currents. Stimulation protocols
were generated and signals acquired using the WinLTP program (WinLTP,
The University of Bristol, Bristol, UK) on a personal computer.
Expression of Genetically Encoded GCaMP6f and Imaging
TH-Cre rats were anesthetized with isoflurane, and AAV1.Syn.Flex.GCaMP6f.
WPRE.SV40 virus (titer: 1012 genomes/ml, 500 nl each site, UPENN Vector
Core) was injected bilaterally into VTA (from bregma, A/P: 5.4 mm; M/L: ±
0.7mm; D/V:8.0mm), using amicro pump (UltraMicroPump,WPI, 100 nl/min)
and Hamilton syringe (1701RN) with hypodermic tubing (30 gauge). The tubing
was left in place for 5 min after completion of the injection.
Two to three weeks after surgery, GCaMP6f fluorescence was observed
using a confocal microscope (LSM710, Zeiss,W Plan-Apochromat 203 objec-
tive) and 488 nm laser in slices in aCSF. Images were collected at 0.5 Hz. After2006 Cell Reports 12, 1997–2008, September 29, 2015 ª2015 The A5–10 min of baseline, slices were exposed to drug for 20 min. Image stacks
were processed and analyzed offline with ImageJ (NIH). When observed, a
StackReg plug-in was used to correct x-y drift. Regions of interests were
defined over cell bodies. The time-lapse signal was expressed asDF/F0, where
F0 is the baseline fluorescence and DF = F – F0. The frequency of calcium os-
cillations was determined by fast Fourier transformation (FFT) of the signal.
Half-width was measured using Event Detection in Clampfit 9 (Molecular De-
vices). Cross correlation of the calcium signals was performed in Clampfit 9,
and the peak correlation coefficient was chosen within a ±10-s window.
Measurement of DA Transients In Vivo Using FSCV
Male Sprague-Dawley rats purchased with implanted jugular vein catheters
(n = 9, 300–350 g; Charles Rivers) were anesthetized with isoflurane. A guide
cannula (Bioanalytical Systems) was positioned above the NAc shell (from
bregma, A/P: +1.7 mm, M/L: +0.8 mm, D/V: 2.5 mm), and a combination
bipolar stimulating electrode/steel guide cannula (26 gauge; Plastics One)
was implanted ipsilaterally targeting the VTA (from bregma, A/P: 5.4 mm,
M/L: 1.2 mm, D/V: 8.2 mm). An Ag/AgCl reference electrode was placed in
contralateral cortex. All components were permanently affixed with dental
cement. Animals were allowed 3–5 days for recovery.
FSCV was used to monitor DA release using a triangular input waveform
(0.4 V to 1.3 V, 400 V/s) at 10 Hz, applied to a glass-encased carbon fiber elec-
trode lowered into the NAc. Endogenous and electrically evoked (biphasic;
2 ms/phase, 24 pulse, 60 Hz, 125 mA) DA release was recorded prior to the
experimental session to verify electrode performance and create a training
set for principal component regression (PCR) to extract the DA component
from the raw voltammetric data. Rapid DA concentration changes (i.e., DA
‘‘transients’’) were analyzed using Mini Analysis (Synaptosoft) and custom
written MATLAB (The MathWorks) routines to determine drug effects on tran-
sient frequency and amplitude (Cheer et al., 2007).
Intra-VTA infusions of vehicle, rimonabant, or tetrahydrolipstatin (THL)
occurred in the experimental chamber using amicroprocessor-controlled infu-
sion pump (Harvard Apparatus) at a flow rate of 0.5 ml/min. An infusion needle
was inserted through a guide cannula ending 1 mm above the tip of the bipolar
stimulating electrode (Plastics One); the needle was cut to extend 1 mm
beyond the cannula tip. A within-subjects design was used where animals first
received microinfusions of vehicle, followed by 3 mg/kg intravenous cocaine.
A second infusion of rimonabant or THL occurred after the baseline frequency
of DA transients was reestablished (45–60 min) and preceded a second
cocaine injection (3 mg/kg).
Drugs
For in vitro experiments, drugs were first dissolved in vehicle to make 1,000- or
10,000-fold concentrated stock solutions. The drugs were then applied
to the slices by diluting the stock solution in the perfusion reservoir.
DNQX, D-()-2-amino-5-phosphonopentanoic acid (D-AP5), GR55562,
HEAT, JNJ16259685, MTEP, AM 251, THL, phenylephrine, sumatriptan, and
U73122 were purchased from Tocris. Picrotoxin was purchased from Sigma.
AAV1.Syn.Flex.GCaMP6f was purchased from the University of Pennsylvania
Vector Core. 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-3-[(E)-piperi-
dinoiminomethyl]-1H-pyrazole (PIMSR1) was provided by Dr. Herbert H. Seltz-
man at Research Triangle Institute (NIDA, Raleigh, NC; RTI International). For
FSCVexperiments, cocaine (Sigma-Aldrich)was dissolved in saline, rimonabant
(SR141716A; RTI), and THL (Sigma-Aldrich) were freshly suspended in a 1:1:18
ratio of ethanol, emulphor (Alkamuls EL-620; Rhodia), and saline (0.9%).
Data Analysis
Group data are presented as the mean ± SEM in all cases. All statistical tests,
including t tests, one-way ANOVAs, and K-S tests were performed using
GraphPad Prism 5 (GraphPad Software). Post hoc analysis (Bonferroni test)
was performed when an ANOVA yielded a significant (p < 0.05) main effect.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one movie, and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2015.08.041.uthors
AUTHOR CONTRIBUTIONS
H.W., C.R.L., and J.F.C. conceived the study. H.W. collected and analyzed
most of the electrophysiological and calcium imaging data. T.T. collected
some of the electrophysiological data. D.P.C. collected and analyzed all of
the in vivo data. All authors contributed to writing the manuscript.
ACKNOWLEDGMENTS
The AAV1.Syn.Flex.GCaMP6f.WPRE.SV40 virus was generously made avail-
able by Vivek Jayaraman, PhD, Rex A. Kerr, PhD, Douglas S. Kim, PhD, Loren
L. Looger, PhD, Karel Svoboda, PhD, and the GENIE Project, Janelia Farms,
Howard Hughes Medical Institute. The TH-cre rat breeders were donated by
Dr. Karl Deisseroth to the NIDA-IRP Optogenetic and Transgenic Core. We
thank Drs. Antonello Bonci and Alexander Hoffman for critically reading the
manuscript. The work was funded by the NIH/NIDA-Intramural Research Pro-
gram (C.R.L., H.W., and T.T.), and NIDA extramural grants DA022340,
DA033926 (J.F.C.).
Received: March 2, 2015
Revised: June 2, 2015
Accepted: August 11, 2015
Published: September 10, 2015
REFERENCES
Alger, B.E., and Kim, J. (2011). Supply and demand for endocannabinoids.
Trends Neurosci. 34, 304–315.
Aragona, B.J., Cleaveland, N.A., Stuber, G.D., Day, J.J., Carelli, R.M., and
Wightman, R.M. (2008). Preferential enhancement of dopamine transmission
within the nucleus accumbens shell by cocaine is attributable to a direct in-
crease in phasic dopamine release events. J. Neurosci. 28, 8821–8831.
Auclair, A., Cotecchia, S., Glowinski, J., and Tassin, J.P. (2002). D-amphet-
amine fails to increase extracellular dopamine levels in mice lacking alpha
1b-adrenergic receptors: relationship between functional and nonfunctional
dopamine release. J. Neurosci. 22, 9150–9154.
Cameron, D.L., and Williams, J.T. (1994). Cocaine inhibits GABA release in the
VTA through endogenous 5-HT. J. Neurosci. 14, 6763–6767.
Cheer, J.F., Wassum, K.M., Sombers, L.A., Heien, M.L.A.V., Ariansen, J.L.,
Aragona, B.J., Phillips, P.E.M., and Wightman, R.M. (2007). Phasic dopamine
release evoked by abused substances requires cannabinoid receptor activa-
tion. J. Neurosci. 27, 791–795.
Chieng, B., Azriel, Y., Mohammadi, S., and Christie, M.J. (2011). Distinct
cellular properties of identified dopaminergic and GABAergic neurons in the
mouse ventral tegmental area. J. Physiol. 589, 3775–3787.
Cooper, D.C. (2002). The significance of action potential bursting in the brain
reward circuit. Neurochem. Int. 41, 333–340.
Covey, D.P., Roitman, M.F., and Garris, P.A. (2014). Illicit dopamine transients:
reconciling actions of abused drugs. Trends Neurosci. 37, 200–210.
De Vries, T.J., Shaham, Y., Homberg, J.R., Crombag, H., Schuurman, K., Die-
ben, J., Vanderschuren, L.J., and Schoffelmeer, A.N. (2001). A cannabinoid
mechanism in relapse to cocaine seeking. Nat. Med. 7, 1151–1154.
Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin,
G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992). Isola-
tion and structure of a brain constituent that binds to the cannabinoid receptor.
Science 258, 1946–1949.
Di Chiara, G., and Bassareo, V. (2007). Reward system and addiction: what
dopamine does and doesn’t do. Curr. Opin. Pharmacol. 7, 69–76.
Di Chiara, G., and Imperato, A. (1988). Drugs abused by humans preferentially
increase synaptic dopamine concentrations in the mesolimbic system of freely
moving rats. Proc. Natl. Acad. Sci. USA 85, 5274–5278.
Einhorn, L.C., Johansen, P.A., and White, F.J. (1988). Electrophysiological
effects of cocaine in the mesoaccumbens dopamine system: studies in the
ventral tegmental area. J. Neurosci. 8, 100–112.Cell RepFiorillo, C.D., andWilliams, J.T. (1998). Glutamate mediates an inhibitory post-
synaptic potential in dopamine neurons. Nature 394, 78–82.
French, E.D., Dillon, K., andWu, X. (1997). Cannabinoids excite dopamine neu-
rons in the ventral tegmentum and substantia nigra. Neuroreport 8, 649–652.
Gessa, G.L., Melis, M., Muntoni, A.L., and Diana, M. (1998). Cannabinoids
activate mesolimbic dopamine neurons by an action on cannabinoid CB1 re-
ceptors. Eur. J. Pharmacol. 341, 39–44.
Goertz, R.B., Wanat, M.J., Gomez, J.A., Brown, Z.J., Phillips, P.E., and Pala-
dini, C.A. (2014). Cocaine increases dopaminergic neuron and motor activity
via midbrain a1 adrenergic signaling. Neuropsychopharmacology, Published
online November 6, 2014. http://dx.doi.org/10.1038/npp.2014.296.
Hashimotodani, Y., Ohno-Shosaku, T., Tsubokawa, H., Ogata, H., Emoto, K.,
Maejima, T., Araishi, K., Shin, H.S., and Kano, M. (2005). Phospholipase Cbeta
serves as a coincidence detector through its Ca2+ dependency for triggering
retrograde endocannabinoid signal. Neuron 45, 257–268.
Hashimotodani, Y., Ohno-Shosaku, T., and Kano, M. (2007). Ca(2+)-assisted
receptor-driven endocannabinoid release: mechanisms that associate pre-
synaptic and postsynaptic activities. Curr. Opin. Neurobiol. 17, 360–365.
Hoffman, A.F., and Lupica, C.R. (2013). Synaptic targets of D9-tetrahydrocan-
nabinol in the central nervous system. Cold Spring Harb. Perspect. Med. 3,
a012203.
Hurst, D., Umejiego, U., Lynch, D., Seltzman, H., Hyatt, S., Roche, M., McAllis-
ter, S., Fleischer, D., Kapur, A., Abood, M., et al. (2006). Biarylpyrazole inverse
agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide
oxygen/lysine3.28(192) interaction. J. Med. Chem. 49, 5969–5987.
Jones, B.E., Halaris, A.E., McIlhany, M., and Moore, R.Y. (1977). Ascending
projections of the locus coeruleus in the rat. I. Axonal transport in central
noradrenaline neurons. Brain Res. 127, 1–21.
Kalivas, P.W., and Duffy, P. (1995). D1 receptors modulate glutamate trans-
mission in the ventral tegmental area. J. Neurosci. 15, 5379–5388.
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., andWata-
nabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission.
Physiol. Rev. 89, 309–380.
Kim, J., Isokawa, M., Ledent, C., and Alger, B.E. (2002). Activation of musca-
rinic acetylcholine receptors enhances the release of endogenous cannabi-
noids in the hippocampus. J. Neurosci. 22, 10182–10191.
Kortleven, C., Fasano, C., Thibault, D., Lacaille, J.C., and Trudeau, L.E. (2011).
The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation
of glutamatergic synapses onto ventral tegmental area dopamine neurons in
mice. Eur. J. Neurosci. 33, 1751–1760.
Koulchitsky, S., De Backer, B., Quertemont, E., Charlier, C., and Seutin, V.
(2012). Differential effects of cocaine on dopamine neuron firing in awake
and anesthetized rats. Neuropsychopharmacology 37, 1559–1571.
Kreitzer, A.C., and Regehr, W.G. (2001). Retrograde inhibition of presynaptic
calcium influx by endogenous cannabinoids at excitatory synapses onto
Purkinje cells. Neuron 29, 717–727.
Landsman, R.S., Burkey, T.H., Consroe, P., Roeske, W.R., and Yamamura,
H.I. (1997). SR141716A is an inverse agonist at the human cannabinoid CB1
receptor. Eur. J. Pharmacol. 334, R1–R2.
Li, X., Hoffman, A.F., Peng, X.Q., Lupica, C.R., Gardner, E.L., and Xi, Z.X.
(2009). Attenuation of basal and cocaine-enhanced locomotion and nucleus
accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psycho-
pharmacology (Berl.) 204, 1–11.
Lupica, C.R., and Riegel, A.C. (2005). Endocannabinoid release frommidbrain
dopamine neurons: a potential substrate for cannabinoid receptor antagonist
treatment of addiction. Neuropharmacology 48, 1105–1116.
Lupica, C.R., Riegel, A.C., and Hoffman, A.F. (2004). Marijuana and cannabi-
noid regulation of brain reward circuits. Br. J. Pharmacol. 143, 227–234.
Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A., and Kano,M. (2001). Presyn-
aptic inhibition caused by retrograde signal from metabotropic glutamate to
cannabinoid receptors. Neuron 31, 463–475.orts 12, 1997–2008, September 29, 2015 ª2015 The Authors 2007
Maejima, T., Oka, S., Hashimotodani, Y., Ohno-Shosaku, T., Aiba, A., Wu, D.,
Waku, K., Sugiura, T., and Kano, M. (2005). Synaptically driven endocannabi-
noid release requires Ca2+-assisted metabotropic glutamate receptor sub-
type 1 to phospholipase Cbeta4 signaling cascade in the cerebellum.
J. Neurosci. 25, 6826–6835.
Ma´tya´s, F., Urba´n, G.M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T.F.,
and Katona, I. (2008). Identification of the sites of 2-arachidonoylglycerol
synthesis and action imply retrograde endocannabinoid signaling at both
GABAergic and glutamatergic synapses in the ventral tegmental area. Neuro-
pharmacology 54, 95–107.
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E.,
Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., et al.
(1995). Identification of an endogenous 2-monoglyceride, present in canine
gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90.
Mejı´as-Aponte, C.A., Drouin, C., and Aston-Jones, G. (2009). Adrenergic and
noradrenergic innervation of the midbrain ventral tegmental area and retroru-
bral field: prominent inputs from medullary homeostatic centers. J. Neurosci.
29, 3613–3626.
Mejias-Aponte, C.A., Ye, C., Bonci, A., Kiyatkin, E.A., and Morales, M. (2015).
A subpopulation of neurochemically-identified ventral tegmental area dopa-
mine neurons is excited by intravenous cocaine. J. Neurosci. 35, 1965–1978.
Melis, M., Pistis, M., Perra, S., Muntoni, A.L., Pillolla, G., and Gessa, G.L.
(2004). Endocannabinoids mediate presynaptic inhibition of glutamatergic
transmission in rat ventral tegmental area dopamine neurons through activa-
tion of CB1 receptors. J. Neurosci. 24, 53–62.
Ohno-Shosaku, T., Maejima, T., and Kano, M. (2001). Endogenous cannabi-
noids mediate retrograde signals from depolarized postsynaptic neurons to
presynaptic terminals. Neuron 29, 729–738.
Oleson, E.B., Beckert, M.V., Morra, J.T., Lansink, C.S., Cachope, R., Abdullah,
R.A., Loriaux, A.L., Schetters, D., Pattij, T., Roitman, M.F., et al. (2012). Endo-
cannabinoids shape accumbal encoding of cue-motivated behavior via CB1
receptor activation in the ventral tegmentum. Neuron 73, 360–373.
Pan, B., Hillard, C.J., and Liu, Q.-S. (2008). Endocannabinoid signaling
mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine
neurons. J. Neurosci. 28, 1385–1397.
Phillips, P.E.M., Stuber, G.D., Heien, M.L.A.V., Wightman, R.M., and Carelli,
R.M. (2003). Subsecond dopamine release promotes cocaine seeking. Nature
422, 614–618.
Reith, M.E., Li, M.Y., and Yan, Q.S. (1997). Extracellular dopamine, norepi-
nephrine, and serotonin in the ventral tegmental area and nucleus accumbens
of freely moving rats during intracerebral dialysis following systemic adminis-2008 Cell Reports 12, 1997–2008, September 29, 2015 ª2015 The Atration of cocaine and other uptake blockers. Psychopharmacology (Berl.) 134,
309–317.
Riegel, A.C., and Lupica, C.R. (2004). Independent presynaptic and postsyn-
aptic mechanisms regulate endocannabinoid signaling at multiple synapses
in the ventral tegmental area. J. Neurosci. 24, 11070–11078.
Ritz, M.C., Lamb, R.J., Goldberg, S.R., and Kuhar, M.J. (1987). Cocaine recep-
tors on dopamine transporters are related to self-administration of cocaine.
Science 237, 1219–1223.
Roitman, M.F., Stuber, G.D., Phillips, P.E.M., Wightman, R.M., and Carelli,
R.M. (2004). Dopamine operates as a subsecond modulator of food seeking.
J. Neurosci. 24, 1265–1271.
Sombers, L.A., Beyene, M., Carelli, R.M., and Wightman, R.M. (2009). Synap-
tic overflow of dopamine in the nucleus accumbens arises from neuronal
activity in the ventral tegmental area. J. Neurosci. 29, 1735–1742.
Soria, G., Mendiza´bal, V., Tourin˜o, C., Robledo, P., Ledent, C., Parmentier, M.,
Maldonado, R., and Valverde, O. (2005). Lack of CB1 cannabinoid receptor im-
pairs cocaine self-administration. Neuropsychopharmacology 30, 1670–1680.
Steinberg, E.E., Boivin, J.R., Saunders, B.T., Witten, I.B., Deisseroth, K., and
Janak, P.H. (2014). Positive reinforcement mediated by midbrain dopamine
neurons requires D1 and D2 receptor activation in the nucleus accumbens.
PLoS ONE 9, e94771.
Sulzer, D. (2011). How addictive drugs disrupt presynaptic dopamine neuro-
transmission. Neuron 69, 628–649.
Szabo, B., Siemes, S., and Wallmichrath, I. (2002). Inhibition of GABAergic
neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neu-
rosci. 15, 2057–2061.
Thomsen, M., Han, D.D., Gu, H.H., and Caine, S.B. (2009). Lack of cocaine
self-administration in mice expressing a cocaine-insensitive dopamine trans-
porter. J. Pharmacol. Exp. Ther. 331, 204–211.
Wilson, R.I., and Nicoll, R.A. (2001). Endogenous cannabinoids mediate retro-
grade signalling at hippocampal synapses. Nature 410, 588–592.
Wise, R.A., and Rompre, P.P. (1989). Brain dopamine and reward. Annu. Rev.
Psychol. 40, 191–225.
Xi, Z.X., Gilbert, J.G., Peng, X.Q., Pak, A.C., Li, X., and Gardner, E.L. (2006).
Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse
in rats: role of glutamate in the nucleus accumbens. J. Neurosci. 26, 8531–
8536.
Xi, Z.X., Spiller, K., Pak, A.C., Gilbert, J., Dillon, C., Li, X., Peng, X.Q., andGard-
ner, E.L. (2008). Cannabinoid CB1 receptor antagonists attenuate cocaine’s
rewarding effects: experiments with self-administration and brain-stimulation
reward in rats. Neuropsychopharmacology 33, 1735–1745.uthors
